Clinical Trial Update: Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating osimertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Egfr-mutant Lung Cancers
• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Osimertinib (osimertinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Non-small Cell Lung Cancer, EGFR-mutant Lung Cancers | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-09-22